| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Imatinib Mesylate | FAERS: 2 | US FAERS | |
| 2 | venetoclax | FAERS: 2 | US FAERS | |
| 3 | Abiraterone Acetate | FAERS: 1 | US FAERS | |
| 4 | Cabozantinib S-malate | FAERS: 1 | US FAERS | |
| 5 | Erlotinib Hydrochloride | FAERS: 1 | US FAERS | |
| 6 | Fulvestrant | FAERS: 1 | US FAERS | |
| 7 | Lenalidomide | FAERS: 1 | US FAERS | |
| 8 | PCI 32765 | FAERS: 1 | US FAERS | |
| 9 | Temozolomide | FAERS: 1 | US FAERS | |
| 10 | gemcitabine | FAERS: 1 | US FAERS | |
| 11 | gemcitabine | FAERS: 1 | US FAERS | |
| 12 | olaparib | FAERS: 1 | US FAERS | |
| 13 | pazopanib | FAERS: 1 | US FAERS | |
| 14 | regorafenib | FAERS: 1 | US FAERS |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.